IKT
Price:
$2.62
Market Cap:
$176.04M
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in ...[Read more]
Industry
Biotechnology
IPO Date
2020-12-23
Stock Exchange
NASDAQ
Ticker
IKT
According to Inhibikase Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 173.14M. This represents a change of 6.73% compared to the average of 2.53M of the last 4 quarters.
The mean historical Enterprise Value of Inhibikase Therapeutics, Inc. over the last ten years is 50.98M. The current 173.14M Enterprise Value has changed 33.86% with respect to the historical average. Over the past ten years (40 quarters), IKT's Enterprise Value was at its highest in in the September 2020 quarter at 81.87M. The Enterprise Value was at its lowest in in the June 2022 quarter at -13460170.32.
Average
50.98M
Median
66.61M
Minimum
-13733703.88
Maximum
102.62M
Discovering the peaks and valleys of Inhibikase Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 32.40%
Maximum Annual Enterprise Value = 102.62M
Minimum Annual Increase = -142.00%
Minimum Annual Enterprise Value = -13733703.88
Year | Enterprise Value | Change |
---|---|---|
2023 | -1770144.08 | -130.69% |
2022 | 5.77M | -142.00% |
2021 | -13733703.88 | -124.65% |
2020 | 55.72M | -45.66% |
2019 | 102.53M | 29.47% |
2018 | 79.19M | -22.83% |
2017 | 102.62M | 32.40% |
The current Enterprise Value of Inhibikase Therapeutics, Inc. (IKT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3245083.99
5-year avg
29.70M
10-year avg
50.98M
Inhibikase Therapeutics, Inc.’s Enterprise Value is less than DiaMedica Therapeutics Inc. (173.56M), greater than Milestone Pharmaceuticals Inc. (117.78M), less than Seres Therapeutics, Inc. (277.57M), greater than Oncolytics Biotech Inc. (101.89M), less than scPharmaceuticals Inc. (204.48M), greater than aTyr Pharma, Inc. (138.44M), less than Sio Gene Therapies Inc. (0), greater than Kaleido Biosciences, Inc. (-15427292.00), greater than Tempest Therapeutics, Inc. (4.26K), greater than AN2 Therapeutics, Inc. (14.24M), greater than Miromatrix Medical Inc. (5.61M), greater than PMV Pharmaceuticals, Inc. (90.06M), greater than Anebulo Pharmaceuticals, Inc. (48.39M), greater than Nutriband Inc. (45.92M), greater than Quoin Pharmaceuticals, Ltd. (57.20M), greater than Longeveron Inc. (3.23M), greater than RenovoRx, Inc. (20.53M), greater than Virax Biolabs Group Limited (12.72M), greater than null (5.45M),
Company | Enterprise Value | Market cap |
---|---|---|
173.56M | $187.24M | |
117.78M | $77.79M | |
277.57M | $136.18M | |
101.89M | $88.53M | |
204.48M | $201.62M | |
138.44M | $131.12M | |
0 | $30.70M | |
-15427292.00 | $4.26K | |
4.26K | $25.10M | |
14.24M | $32.38M | |
5.61M | $92.95M | |
90.06M | $84.75M | |
48.39M | $49.01M | |
45.92M | $63.75M | |
57.20M | $2.85M | |
3.23M | $31.16M | |
20.53M | $24.47M | |
12.72M | $8.81M | |
5.45M | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibikase Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Inhibikase Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Inhibikase Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Inhibikase Therapeutics, Inc. (IKT)?
What is the 3-year average Enterprise Value for Inhibikase Therapeutics, Inc. (IKT)?
What is the 5-year average Enterprise Value for Inhibikase Therapeutics, Inc. (IKT)?
How does the current Enterprise Value for Inhibikase Therapeutics, Inc. (IKT) compare to its historical average?